Bayer's Financial Overview

Bayer AG has reported a slight decline in its fourth-quarter sales for fiscal 2024, with figures dropping by 1% to €11.7 billion. The company's full-year sales also saw a decrease, falling by 2.2% to €46.6 billion.

Earnings and Expectations

Despite the challenging year, Bayer's EBITDA for the quarter stood at €1.9 billion, contributing to a full-year EBITDA of €8.7 billion. The company highlighted an improvement in net income for the quarter, reaching €1.3 billion or €1.36 per share. However, the fiscal year ended with a net loss of €2.9 billion or €2.99 per share. Looking ahead, Bayer anticipates its net sales for 2025 to range between €45 and €47 billion.

Challenges and Strategic Focus

Bayer's report underscores the impact of geopolitical uncertainties, including tariffs and foreign exchange fluctuations, on its operations. "2024 was a challenging year for Bayer, marked by volatile business dynamics. The Supervisory Board has concentrated on strategic alignment and addressing critical issues, such as ongoing litigations in the United States, the company's high leverage ratio, and the advancement of the pharmaceutical pipeline," the report concluded.